Indiva Limited

TSXV:NDVA.H Stock Report

Market Cap: CA$5.9m

Indiva Valuation

Is NDVA.H undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NDVA.H when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NDVA.H's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NDVA.H's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NDVA.H?

Key metric: As NDVA.H is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NDVA.H. This is calculated by dividing NDVA.H's market cap by their current revenue.
What is NDVA.H's PS Ratio?
PS Ratio0.2x
SalesCA$37.49m
Market CapCA$5.86m

Price to Sales Ratio vs Peers

How does NDVA.H's PS Ratio compare to its peers?

The above table shows the PS ratio for NDVA.H vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.2x
DHB Delivra Health Brands
0.5x10.6%CA$6.3m
STHZ StateHouse Holdings
0.05xn/aCA$7.7m
BBM Blueberries Medical
20.8xn/aCA$6.0m
APLI Appili Therapeutics
7.5xn/aCA$3.6m
NDVA.H Indiva
0.2xn/aCA$5.9m

Price-To-Sales vs Peers: NDVA.H is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (4x).

Price to Sales Ratio vs Industry

How does NDVA.H's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

31 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.0.7x10.7%
NDVA.H Indiva
 0.2xn/aUS$4.32m
AYR.A Ayr Wellness
0.2x2.6%US$82.37m
IAN iAnthus Capital Holdings
0.3xn/aUS$47.79m
NDVA.H 0.2xIndustry Avg. 0.7xNo. of Companies31PS01.22.43.64.86+
31 CompaniesEstimated GrowthMarket Cap
Industry Avg.0.7x53.0%
NDVA.H Indiva
 0.2xn/aUS$4.32m
No more companies

Price-To-Sales vs Industry: NDVA.H is good value based on its Price-To-Sales Ratio (0.2x) compared to the Canadian Pharmaceuticals industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is NDVA.H's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NDVA.H PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NDVA.H's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Verano Holdings

CA$850.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.38

7D

-10.5%

1Y

-59.6%

Medexus Pharmaceuticals

CA$52.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.11

7D

3.4%

1Y

37.9%

Fennec Pharmaceuticals

US$117.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$5.69

7D

-5.8%

1Y

-51.2%